NEW YORK, Dec. 5 (GenomeWeb News) - Prolexys Pharmaceuticals, formerly Myriad Proteomics, announced today that it is collaborating with the Whitehead Institute to use compounds from Whitehead and Prolexys' HySpec mass spec platform and chemiproteomic techniques to find new oncology targets.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.